Pathstone Family Office
ONCE

Pathstone Family Office’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Pathstone Family Office’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-59
Closed -$7K – 982
2019
Q1 		$7K Hold
59
– – ﹤0.01% 561
2018
Q4 		$2K Buy
+59
New +$2.56K ﹤0.01% 497

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Pathstone Family Office's ONCE Position: Q2 2019 in Review

Pathstone Family Office sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2019, closing a stake of 59 shares — an estimated $7K sold.

Pathstone Family Office first reported a position in ONCE in Q4 2018 and held it in 2 quarters. The position peaked at $7K in Q1 2019. 194 funds tracked by Wall St. Rank hold ONCE as of Q2 2019.

  • Pathstone Family Office reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Pathstone Family Office sold 59 Spark Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $7K.
  • Pathstone Family Office first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Pathstone Family Office's Spark Therapeutics, Inc. Common Stock position peaked at $7K in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Pathstone Family Office's 13F filing for Q2 2019, filed 14 Aug 2019.